Menu
Peptide Database
Results
No peptides found
Featured

Use search to browse all 100+ peptides

LL-37

Cathelicidin, hCAP-18, FALL-39, CAP-18

Quick Stats
Studies 2230
Trials 95
Score 2
2020 pubmed 109 citations

Therapeutic Potential of Cathelicidin Peptide LL-37, an Antimicrobial Agent, in a Murine Sepsis Model.

Nagaoka. Isao I; Tamura. Hiroshi H; Reich. Johannes J

Key Findings

  • LL‑37 increased survival of mice with sepsis
  • It reduced inflammatory macrophage pyroptosis and cytokine release
  • It enhanced neutrophil NET formation and release of antimicrobial microvesicles

Practical Outcomes

  • Right now the findings are pre‑clinical, so there’s no safe dosage or protocol for humans. It signals that LL‑37 might become a future treatment for severe infections, but biohackers should wait for human trials before trying it.

Summary

In a mouse model of severe infection, the natural peptide LL‑37 helped the animals survive by calming down harmful inflammation and boosting the immune system's ability to trap and kill bacteria. The study shows LL‑37 can block a type of inflammatory cell death and encourage immune cells to release antibacterial structures, but all the work was done in mice, not people.

Abstract

Among the mechanisms put-up by the host to defend against invading microorganisms, antimicrobial peptides represent the first line. In different species of mammals, the cathelicidin family of antimicrobial peptides AMPs has been identified, and in humans, LL-37 is the only type of cathelicidin identified. LL-37 has many different biological activities, such as regulation of responses to inflammation, besides its lipopolysaccharide (LPS)-neutralizing and antimicrobial and activities. Recently, employing a murine septic model that involves cecal ligation and puncture (CLP), we examined the effect of LL-37. The results indicated that LL-37 exhibits multiple protective actions on septic mice; firstly, the survival of CLP mice was found to be improved by LL-37 by the suppression of the macrophage pyroptosis that induces the release of pro-inflammatory cytokines (such as IL-1β) and augments inflammatory reactions in sepsis; secondly, the release of neutrophil extracellular traps (NETs), which have potent bactericidal activity, is enhanced by LL-37, and protects mice from CLP-induced sepsis; thirdly, LL-37 stimulates neutrophils to release antimicrobial microvesicles (ectosomes), which improve the pathological condition of sepsis. These findings indicate that LL-37 protects CLP septic mice through at least three mechanisms, i.e., the suppression of pro-inflammatory macrophage pyroptosis and the release of antimicrobial NETs (induction of NETosis) and ectosomes from neutrophils. Thus, LL-37 can be a potential therapeutic candidate for sepsis due to its multiple properties, including the modulation of cell death (pyroptosis and NETosis) and the release of antimicrobial NETs and ectosomes as well as its own bactericidal and LPS-neutralizing activities.

Study Information

Provider

pubmed

Year

2020

Date

2020-08-19T00:00:00.000Z

DOI

10.3390/ijms21175973

Citations

109

References

60